Takeda announces fda acceptance of bla resubmission for investigational subcutaneous administration of entyvio® (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food and drug administration (fda) has accepted for review its biologics license application (bla) resubmission for the investigational subcutaneous (sc) administration of entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (uc) after induction therapy with entyvio intravenous. the resubmission is intended to address fda.
TAK Ratings Summary
TAK Quant Ranking